medigraphic.com
Colegio de Medicina Interna de México.

2023, Number 6

<< Back Next >>

Med Int Mex 2023; 39 (6)

Human albumin: evidence-based guidelines

Garnica CCE

Language: Spanish
References: 47
Page: 908-919
PDF size: 237.17 Kb.


ABSTRACT

Albumin is the most abundant circulating protein in the body and its clinical importance has been unraveled over time. Since 1940 it has been used in different clinical scenarios. Its protective properties of the microvasculature and the glycocalyx are those that are considered when treating patients with endothelial damage (hypovolaemia, sepsis, burns); however, there are no detailed indications for its use. This review will break down accepted indications and suggest protocols for conscientious use.


REFERENCES

  1. Italian Association for the Study of the Liver (AISF); ItalianSociety of Transfusion Medicine and Immunohaematology(SIMTI). AISF-SIMTI Position Paper: The appropriate use ofalbumin in patients with liver cirrhosis. Dig Liver Dis 2016;48 (1): 4-15. Doi: 10.1016/j.dld.2015.11.008.

  2. Fanali G, di Masi A, Trezza V, Marino M, et al. Human serumalbumin: from bench to bedside. Mol Aspects Med 2012;

  3. 33: 209-90. Doi: 10.1016/j.mam.2011.12.002.3. Peters T. All about albumin: biochemistry, genetics, andmedical applications. United States: Academic Press, 1995.https://doi.org/10.1016/B978-0-12-552110-9.X5000-4.

  4. Skillman JJ, Restall DS, Salzman EW. Randomized trial ofalbumin vs. electrolyte solutions during abdominal aorticoperations. Surgery 1975; 78 (3): 291-303.

  5. Cochrane Injuries Group Albumin Reviewers. Human albuminadministration in critically ill patients: systematic reviewof randomised controlled trials. BMJ 1998; 317 (7153):235-240. https://doi.org/10.1136/bmj.317.7153.235.

  6. Wilkes MM, Navickis RJ. Patient survival after humanalbumin administration. A meta-analysis of randomized,controlled trials. Ann Intern Med 2001; 135 (3):149-64. Doi:10.7326/0003-4819-135-3-200108070-00007.

  7. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, NortonR; SAFE Study Investigators. A comparison of albumin andsaline for fluid resuscitation in the intensive care unit.N Engl J Med 2004; 350 (22): 2247-56. Doi: 10.1056/NEJMoa040232.

  8. Caironi P, Tognoni G, Masson S, Fumagalli R, et al. Albuminreplacement in patients with severe sepsis or septic shock.N Engl J Med 2014; 370 (15): 1412-1421. doi:10.1056/NEJMoa1305727.

  9. Annane D, Siami S, Jaber S, Martin C, et al. Effects of fluidresuscitation with colloids vs crystalloids on mortality incritically ill patients presenting with hypovolemic shock:The CRISTAL randomized trial. JAMA 2013; 310 (17): 1809-1817. Doi: 10.1001/jama.2013.280502.

  10. Patel A, Laffan MA, Waheed U, Brett SJ. Randomised trialsof human albumin for adults with sepsis: systematic reviewand meta-analysis with trial sequential analysis of all-causemortality [published correction appears in BMJ. 2014; 349:g4850]. BMJ 2014; 349: g4561. doi:10.1136/bmj.g4561.

  11. Consejo de Salubridad General (2017). Cuadro Básico y Catálogode Medicamentos. http://www.csg.gob.mx/descargas/pdf/priorizacion/cuadro-basico/med/catalogo/2017/EDICION_2017_MEDICAMENTOS-FINAL.pdf.

  12. US Food & Drug Administration. (2018). Albumin (Human)(None). https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/albumin-human-none.

  13. Bernardi M, Angeli P, Claria J, Moreau R, et al. Albuminin decompensated cirrhosis: new concepts and perspectives.Gut 2020; 69 (6): 1127-1138. Doi: 10.1136/gutjnl-2019-318843.

  14. Bosques-Padilla FJ, Rivera-Ramos JF, Rizo-Robles MT,Medina-González A, Torres-Flores E. Guías clínicas dediagnóstico y tratamiento de la ascitis. Aspectos terapéuticosde la ascitis no complicada. Rev Gastroenterol Mex2009; 74 (4).

  15. Castro-Narro G, Moctezuma-Velázquez C, Male-VelázquezR, Trejo-Estrada R, et al. Position statement on the useof albumin in liver cirrhosis. Ann Hepatol 2022; 27 (4):100708. doi:10.1016/j.aohep.2022.100708.

  16. Wong F, Pappas C, Curry MP, Reddy R, et al. Terlipressinplus albumin for the treatment of type 1 hepatorenalsyndrome. N Engl J Med 2021; 384:818-828. Doi: 10.1056/NEJMoa2008290.

  17. Carvalho JR, Verdelho Machado M. New insights aboutalbumin and liver disease. Ann Hepatol 2018; 17 (4): 547-560. Doi: 10.5604/01.3001.0012.0916.

  18. Yu YT, Liu J, Hu B, Wang RL, et al. Expert consensus on theuse of human serum albumin in critically ill patients. ChinMed J (Engl) 2021; 134 (14): 1639-1654. doi:10.1097/CM9.0000000000001661.

  19. Evans L, Rhodes A, Alhazzani W, Antonelli M, et al. Survivingsepsis campaign: international guidelines for managementof sepsis and septic shock 2021. Intensive Care Med 2021;47 (11): 1181-1247. doi:10.1007/s00134-021-06506-y.

  20. Zhou S, Zeng Z, Wei H, Sha T, An S. Early combination of albuminwith crystalloids administration might be beneficialfor the survival of septic patients: a retrospective analysisfrom MIMIC-IV database. Ann Intensive Care 2021; 11 (1):42. doi:10.1186/s13613-021-00830-8.

  21. Sakr Y, Gattinoni L; SepNet-Critical-Care-Trials-Gruppe.Randomisierte kontrollierte multizentrische Studie zur Albuminersatztherapieim septischen Schock (ARISS) [Randomizedcontrolled multicenter study of albumin replacementtherapy in septic shock (ARISS)]. Anaesthesist 2021; 70(6): 528-530. German. Doi: 10.1007/s00101-021-00952-5.

  22. Jeschke MG, van Baar ME, Choudhry MA, Chung KK, GibranNS, Logsetty S. Burn injury. Nat Rev Dis Primers 2020; 6 (1):11. doi:10.1038/s41572-020-0145-5.

  23. Causbie JM, Sattler LA, Basel AP, Britton GW, Cancio LC.State of the art: An update on adult burn resuscitation.Eur Burn J 2021; 2 (3): 152-167. https://doi.org/10.3390/ebj2030012.

  24. Navickis RJ, Greenhalgh DG, Wilkes MM. Albumin in burnshock resuscitation: A meta-analysis of controlled clinicalstudies. J Burn Care Res 2016; 37 (3): e268-e278. Doi:10.1097/BCR.0000000000000201.

  25. Haberal M, Abali S, Karakayali H. Fluid management inmajor burns injuries. Indian J Plast Surg 2010; 43. Doi:10.4103/0970-0358.70715.

  26. Chung KK, Wolf SE, Cancio LC, Alvarado R, et al. Resuscitationof severely burned military casualties: fluid begetsmore fluid. J Trauma 2009; 67 (2): 231-237. doi:10.1097/TA.0b013e3181ac68cf.

  27. Satahoo SS, Palmieri TL. Fluid resuscitation in burns: 2 cc,3 cc, or 4 cc? Curr Trauma 2019; Rep 5: 99-105 (2019).https://doi.org/10.1007/s40719-019-00166-6.

  28. Vincent JL, Russell JA, Jacob M, Martin G, et al. Albuminadministration in the acutely ill: what is new and wherenext? Critical Care 2014; 18: 231. doi: 10.1186/cc13991.

  29. Vincent JL, Dubois MJ, Navickis RJ, Wilkes MM. Hypoalbuminemiain acute illness: is there a rationale for intervention?A meta-analysis of cohort studies and controlledtrials. Ann Surg 2003; 237 (3): 319-34. doi: 10.1097/01.SLA.0000055547.93484.87.

  30. Myburgh JA, Finfer S. Albumin is a blood product too—isit safe for all patients? Crit Care Resusc 2009; 11: 67-70.

  31. Rozga J, Piatek T, Malkowski P. Human albumin: old, new,and emerging applications. Ann Transplant 2013; 18: 205-217. doi: 10.12659/AOT.889188.

  32. Al-Khafaji, et al. Albumin in the critically ill. TransfusionAlternatives Transfusion Med 2003; 5: 4.

  33. Busuioc RM, Mircescu G. Nephrotic syndrome complications- new and old. Part 1. Maedica (Bucur) 2022; 17(1): 153-168.

  34. Ho JJ, Adnan AS, Kueh YC, Ambak NJ, Van Rostenberghe H,Jummaat F. Human albumin infusion for treating oedema inpeople with nephrotic syndrome. Cochrane Database SystRev 2019; 7 (7): CD009692. 2019. doi:10.1002/14651858.CD009692.pub2.

  35. Kitsios GD, Mascari P, Ettunsi R, Gray AW. Co-administrationof furosemide with albumin for overcoming diureticresistance in patients with hypoalbuminemia: a metaanalysis.J Crit Care 2014; 29 (2): 253-9. doi: 10.1016/j.jcrc.2013.10.004.

  36. Lee TH, Kuo G, Chang CH, et al. Diuretic effect of co-administrationof furosemide and albumin in comparison tofurosemide therapy alone: An updated systematic reviewand meta-analysis. PLoS One 2021; 16 (12): e0260312.doi:10.1371/journal.pone.0260312.

  37. Mendes RS, Pelosi P, Schultz MJ, Rocco PRM, Silva PL. Fluidsin ARDS: more pros than cons. Intensive Care Med Exp2020; 8 (Suppl 1): 32. doi: 10.1186/s40635-020-00319-x.

  38. Silversides JA, Major E, Ferguson AJ, Mann EE, et al.Conservative fluid management or deresuscitation forpatients with sepsis or acute respiratory distress syndromefollowing the resuscitation phase of critical illness: asystematic review and meta-analysis. Intensive Care Med2017; 43 (2): 155-170. doi:10.1007/s00134-016-4573-3.

  39. National Heart, Lung, and Blood Institute Acute RespiratoryDistress Syndrome (ARDS) Clinical Trials Network,Wiedemann HP, Wheeler AP, et al. Comparison of two fluidmanagement strategies in acute lung injury. N Engl J Med2006; 354 (24): 2564-2575. doi:10.1056/NEJMoa062200.

  40. Grissom CK, Hirshberg EL, Dickerson JB, et al. Fluid managementwith a simplified conservative protocol for theacute respiratory distress syndrome. Crit Care Med 2015;43 (2): 288-295. doi:10.1097/CCM.0000000000000715.

  41. Uhlig C, Silva PL, Deckert S, Schmitt J, et al. Albumin versuscrystalloid solutions in patients with the acute respiratorydistress syndrome: a systematic review and meta-analysis.Critical Care 2014; 18: R10. doi: 10.1186/cc13187.

  42. Vlasov H, Juvonen T, Hiippala S, Suojaranta R, et al. Effectand safety of 4% albumin in the treatment of cardiac surgerypatients: study protocol for the randomized, doubleblind,clinical ALBICS (ALBumin In Cardiac Surgery) trial.Trials 2020; 21 (1): 235. doi:10.1186/s13063-020-4160-3.

  43. Moret E, Jacob MW, Ranucci M, Schramko AA. Albumin—beyond fluid replacement in cardiopulmonary bypass surgery:Why, how, and when? Semin Cardiothorac Vasc Anesth2014; 18 (3): 252-259. doi: 10.1177/1089253214535667.

  44. Hanley C, Callum J, Karkouti K, Bartoszko J. Albumin in adultcardiac surgery: a narrative review. L’albumine en chirurgiecardiaque adulte : un compte rendu narratif. Can J Anaesth2021; 68 (8): 1197-1213. doi:10.1007/s12630-021-01991-7.

  45. Wigmore GJ, Anstey JR, St John A, Greaney J, et al. 20%Human albumin solution fluid bolus administration therapyin patients after cardiac surgery (the HAS FLAIR Study).J Cardiothorac Vasc Anesth 2019; 33 (11): 2920-2927.doi:10.1053/j.jvca.2019.03.049.

  46. Gales BJ, Erstad BL. Adverse reactions to human serumalbumin. Ann Pharmacother 1993; 27 (1): 87-94. doi:10.1177/106002809302700119.

  47. Vincent JL, Wilkes MM, Navickis RJ. Safety of human albumin--serious adverse events reported worldwide in 1998-2000.Br J Anaesth 2003; 91 (5): 625-30. doi: 10.1093/bja/aeg233.




2020     |     www.medigraphic.com